Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib – a first-in-class inhibitor of BTK. Off-target kinase inhibitions by ibrutinib are thought to contribute to its adverse events. Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in peripheral blood mononuclear cells and lymph nodes from patients with B-cell malignancies and promising responses in patients with CLL. Described here is a head-to-head Phase III study comparing the efficacy and safety of zanubrutinib with those of ibrutinib in patients with CLL/small lymphocytic lymphoma in the relapsed/refractory setting.

中文翻译：

---

CLL：第二代布鲁顿激酶抑制剂能做什么

慢性淋巴细胞白血病 (CLL) 的治疗标准随着 B 细胞受体信号传导的有效抑制剂的出现而发生了变化，例如 ibrutinib - BTK 的一流抑制剂。依鲁替尼的脱靶激酶抑制被认为是导致其不良事件的原因。Zanubrutinib 是下一代 BTK 抑制剂，具有最小的脱靶效应，BTK 在 B 细胞恶性肿瘤患者的外周血单个核细胞和淋巴结中持续占据，并且在 CLL 患者中具有良好的反应。这里描述的是一项头对头的 III 期研究，比较了 zanubrutinib 与 ibrutinib 在复发/难治性 CLL/小淋巴细胞淋巴瘤患者中的疗效和安全性。